USE OF BOTULINUM TOXIN TYPE A IN THE TREATMENT OF SPASTICITY IN CHILDREN WITH CEREBRAL PALSY

Cerebral palsy has an incidence of about 1-2 per 1000 live births, and in spite of the progress of neonatal medicine, it seems that the incidence will not subside in the near future. The most important characteristic of cerebral palsy is movement abnormality: spasticity, chorea, athetosis, ataxia, d...

Full description

Bibliographic Details
Main Authors: Ljiljana Lazić, Hristina Čolović, Olga Marinković, Marija Spalević, Anita Stanković, Dragan Zlatanović
Format: Article
Language:English
Published: University in Nis, Faculty of Medicine 2011-06-01
Series:Acta Medica Medianae
Subjects:
Online Access:http://publisher.medfak.ni.ac.rs/2011-html/2-broj/952-Ljiljana%20Lazic-USE%20OF%20BOTULINUM%20TOXIN.pdf
id doaj-383ad8c49f734cb9b929d46a45d7bfb8
record_format Article
spelling doaj-383ad8c49f734cb9b929d46a45d7bfb82020-11-24T20:57:21ZengUniversity in Nis, Faculty of MedicineActa Medica Medianae0365-44782011-06-015026367USE OF BOTULINUM TOXIN TYPE A IN THE TREATMENT OF SPASTICITY IN CHILDREN WITH CEREBRAL PALSYLjiljana LazićHristina ČolovićOlga MarinkovićMarija SpalevićAnita StankovićDragan ZlatanovićCerebral palsy has an incidence of about 1-2 per 1000 live births, and in spite of the progress of neonatal medicine, it seems that the incidence will not subside in the near future. The most important characteristic of cerebral palsy is movement abnormality: spasticity, chorea, athetosis, ataxia, dystonia, as well as their different combinations. About 70% of children who suffer from cerebral palsy also suffer from some form of spasticity. Spasticity is a type of muscle hypertonicity characterized by rapid increase in resistance to passive stretching of muscles. The interest for botulinum toxin application in the treatment of spasticity has dramatically increased in the last 10 years. Botulinum toxin is the most powerful neurotoxin that is found in nature. It is produced by anaerobic bacteria – clostridium botulinum. It is produced in eight serotypes of which type A is the most commonly used. Botulinum toxin blocks neuromuscular transmission and causes irreversible weakness of the treated muscle. It has been used since 1993 in the treatment of cerebral palsy in children. The toxin effect is permanent and it results in irreversible denervation. Functional recovery is possible after 2-4 months, due to sprouting of nerve endings and the formation of new synaptic contacts. Treatment with botulinum toxin is safe. Adverse effects are rare, temporary and completely reversible. Application of botulinum toxin prevents or reduces contractures and deformities, and thus delays or avoids surgical treatment. Yet, physical therapy, which prolongs and improves the effects of botulinum toxin, remains an essential and most important form of therapy in the treatment of children with cerebral palsy.http://publisher.medfak.ni.ac.rs/2011-html/2-broj/952-Ljiljana%20Lazic-USE%20OF%20BOTULINUM%20TOXIN.pdfcerebral palsyspasticitybotulinum toxinchildren
collection DOAJ
language English
format Article
sources DOAJ
author Ljiljana Lazić
Hristina Čolović
Olga Marinković
Marija Spalević
Anita Stanković
Dragan Zlatanović
spellingShingle Ljiljana Lazić
Hristina Čolović
Olga Marinković
Marija Spalević
Anita Stanković
Dragan Zlatanović
USE OF BOTULINUM TOXIN TYPE A IN THE TREATMENT OF SPASTICITY IN CHILDREN WITH CEREBRAL PALSY
Acta Medica Medianae
cerebral palsy
spasticity
botulinum toxin
children
author_facet Ljiljana Lazić
Hristina Čolović
Olga Marinković
Marija Spalević
Anita Stanković
Dragan Zlatanović
author_sort Ljiljana Lazić
title USE OF BOTULINUM TOXIN TYPE A IN THE TREATMENT OF SPASTICITY IN CHILDREN WITH CEREBRAL PALSY
title_short USE OF BOTULINUM TOXIN TYPE A IN THE TREATMENT OF SPASTICITY IN CHILDREN WITH CEREBRAL PALSY
title_full USE OF BOTULINUM TOXIN TYPE A IN THE TREATMENT OF SPASTICITY IN CHILDREN WITH CEREBRAL PALSY
title_fullStr USE OF BOTULINUM TOXIN TYPE A IN THE TREATMENT OF SPASTICITY IN CHILDREN WITH CEREBRAL PALSY
title_full_unstemmed USE OF BOTULINUM TOXIN TYPE A IN THE TREATMENT OF SPASTICITY IN CHILDREN WITH CEREBRAL PALSY
title_sort use of botulinum toxin type a in the treatment of spasticity in children with cerebral palsy
publisher University in Nis, Faculty of Medicine
series Acta Medica Medianae
issn 0365-4478
publishDate 2011-06-01
description Cerebral palsy has an incidence of about 1-2 per 1000 live births, and in spite of the progress of neonatal medicine, it seems that the incidence will not subside in the near future. The most important characteristic of cerebral palsy is movement abnormality: spasticity, chorea, athetosis, ataxia, dystonia, as well as their different combinations. About 70% of children who suffer from cerebral palsy also suffer from some form of spasticity. Spasticity is a type of muscle hypertonicity characterized by rapid increase in resistance to passive stretching of muscles. The interest for botulinum toxin application in the treatment of spasticity has dramatically increased in the last 10 years. Botulinum toxin is the most powerful neurotoxin that is found in nature. It is produced by anaerobic bacteria – clostridium botulinum. It is produced in eight serotypes of which type A is the most commonly used. Botulinum toxin blocks neuromuscular transmission and causes irreversible weakness of the treated muscle. It has been used since 1993 in the treatment of cerebral palsy in children. The toxin effect is permanent and it results in irreversible denervation. Functional recovery is possible after 2-4 months, due to sprouting of nerve endings and the formation of new synaptic contacts. Treatment with botulinum toxin is safe. Adverse effects are rare, temporary and completely reversible. Application of botulinum toxin prevents or reduces contractures and deformities, and thus delays or avoids surgical treatment. Yet, physical therapy, which prolongs and improves the effects of botulinum toxin, remains an essential and most important form of therapy in the treatment of children with cerebral palsy.
topic cerebral palsy
spasticity
botulinum toxin
children
url http://publisher.medfak.ni.ac.rs/2011-html/2-broj/952-Ljiljana%20Lazic-USE%20OF%20BOTULINUM%20TOXIN.pdf
work_keys_str_mv AT ljiljanalazic useofbotulinumtoxintypeainthetreatmentofspasticityinchildrenwithcerebralpalsy
AT hristinacolovic useofbotulinumtoxintypeainthetreatmentofspasticityinchildrenwithcerebralpalsy
AT olgamarinkovic useofbotulinumtoxintypeainthetreatmentofspasticityinchildrenwithcerebralpalsy
AT marijaspalevic useofbotulinumtoxintypeainthetreatmentofspasticityinchildrenwithcerebralpalsy
AT anitastankovic useofbotulinumtoxintypeainthetreatmentofspasticityinchildrenwithcerebralpalsy
AT draganzlatanovic useofbotulinumtoxintypeainthetreatmentofspasticityinchildrenwithcerebralpalsy
_version_ 1716787920790093824